Eckert & Ziegler at a Glance German Equity Forum Frankfurt 26 November 2019 Dr. Andreas Eckert CEO 1
Gl Glob obally ally Po Positi sition oned ed for for 25 25 Years Years Nich Ni che Play Player i er in Isoto n Isotope pe M Mark arket et Cancer Radiation Industrial Components Pharmaceuticals (RADIATION THERAPY) (RADIOPHARMA) ( ISOTOPE PRODUCTS ) Production Synthesis Implants LDR Devices Geräte Services Raw materials Applicators LDR API Trading Projects/ Devices HDR API Rohstoffe/ API Disposal Rohstoffe/ API Berlin EUR 33 Mio. EUR 20 Mio. EUR 80 Mio. 25% 16% 59% Strong 3rd Half Year 2019 with Revenues of € 133 Mio. (FY 2018: € 169 Mio.) Slides for Illustration – The spoken word shall be binding 2
From Ja Fro Janu nuary ary 1st 1st 2020: 2020: Medical Seg Med ical Segmen ment t Po Pool ol Cancer Radiation Industrial Components Pharmaceuticals (RADIATION THERAPY) (RADIOPHARMA) ( ISOTOPE PRODUCTS ) Production Synthesis Implants LDR Devices Geräte Services Raw materials Applicators LDR API Trading Projects/ Devices HDR API Rohstoffe/ API Disposal Engineering Rohstoffe/ API From 1.1.2020: MEDICAL Slides for Illustration – The spoken word shall be binding 3
800 800 Employ Employee ees (Head (Headco coun unts ts) ) 19 19 Site Sites s Wo World rldwide wide Result Q3-2019 (Mio. EUR) Revenues 133,2 Net Income 18,8 2% 2 6% 9% 44% 41% EUROPE AMERICA ASIA MIDDLE EAST & AFRICA Slides for Illustration – The spoken word shall be binding 4
Rev Reven enue ues of of Abo About ut € 170 Mio. Mio. in in 2018 2018 18% organic growth in 2018 180 169 160 145 140 138 140 127 120 117 116 120 111 101 100 in Mio. EUR 80 71 60 54 50 42 36 40 33 31 29 24 20 10 8 6 6 4 2 1 0,13 0 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Incl. discontinued and continued operations Slides for Illustration – The spoken word shall be binding 5
Rev Reven enue ues pe per r Seg Segmen ment Q3-2019 Q3 2019 vs vs. . Q3 Q3-2018 2018 , Mio. Euro Total Revenues of 133,2 Mio. EUR in Q3-2019 ( Q3-2018: Euro 123,8 Mio. ) + 8% in Q3-2019 Slides for Illustration – The spoken word shall be binding 6
Net Net Inco Income me Q3 Q3-2019 2019 vs. vs. Q3 Q3-2018 2018 in M in Mio. E io. EUR UR Net Income of 18,8 Mio. EUR in Q3-2019 (Q3-2018 :13,0 Mio. EUR ) + 45% in Q3-2019 Folie nur zur Illustration – es gilt das gesprochene Wort 7
Balance Balan ce She Sheet et as as of of 30 30.09.20 .09.2019 19, , in Mio. EUR Cash 71 Equity 131 Recievables 25 Minority Interests 6 Inventory 31 Loans 18 Intangible Assets 70 Accruals/Provisions 66 Fixed Assets 38 Other Short Term Payables 31 Others 25 Other Long Term Payables 6 Total Activ 259 Total Passiv 259 • Cash and cash equivalents at period end of 71 Mio. EUR • Debt Free (except accounted leasing according to IFRS 16) • Equity Ratio of 53% Slides for Illustration – The spoken word shall be binding 8
Cashflow Cashflow in in Q3 Q3-20 2019 19, , in Mio. EUR EBITDA of 36,6 Mio. EUR Slides for Illustration – The spoken word shall be binding 9
Net Net Liqu Liquidity idity in in Q3 Q3-2019, 2019, in Mio. EUR +10 mm EUR for treasury shares 80 80 70 70 60 60 50 50 In Mio. EUR 40 40 30 30 20 20 10 10 0 0 2014 2015 2016 2017 2018 Q3-2019 Liquidity 22 31 37 58 54 71 Debt 19 16 12 2 0 0 Net Liquidity 3 15 25 56 54 71 Slides for Illustration – The spoken word shall be binding 10
Sha Share re Per Performa formanc nce e and and Dividen Dividend d in in EUR/Share EUR/Share Dividende in EUR / Aktie EUR/Aktie 180 1,20 160 1,10 140 1,00 120 100 0,90 1,2 80 0,80 60 0,70 40 0,60 0,8 20 0,66 0,60 0,60 0,60 0,50 0 2014 2015 2016 2017 2018 2019 Slides for Illustration – The spoken word shall be binding 11
Ov Overview erview • Theranostics • Interventional Radiology • Outlook 12
Str Strat ateg egy / Gr / Growt owth h Opp Oppor ortu tunities nities About tigers, dragons, and other creatures 13
Our Our Top Topics ics • Poor man‘s PET – Theranostics • Dying decently – Interventional Radiology 14
Poor Man‘s PET: Capital Exp Expen en- ditu diture res Bec Become ome Con Consu sumab mables les • A vision comes true Purchase costs incl. Radiopharmacy 6 bis 8 Mio. EUR plus staff • Eckert & Ziegler pionieers first pharmaceutically approved gallium generator worldwide • No need for CAPEX an expensive cyclotron • Transfer of an investment into consumables 15
Comp Complex lex Sup Supply ply Cha Chains ins Bec Become ome Obs Obsolet olete Own Cyclotrons • Berlin-Adlershof • Bonn • Vienna (Seibersdorf) • new: Warsaw Exklusive Distribution • Karlsruhe • Bad Berka 16 Folie nur zur Illustration – es gilt das gesprochene Wort
Globa Global l Mar Marke ket t Ent Entra ranc nce of the of the Gen Gener erat ator or • Opens up precision oncology for the bulk of hospitals • Makes the treatment of niche indications in smaller clinics more attractive Slides only for illustration – the spoken word shall be binding 17
Pre Precision cision Onc Oncolog ology Still Still at at the the Beginning Beginning DIAGNOSIS (Ge-68) THERAPY (Lu-177) Advantage Neuroendocrine tumors • Therapy only for patients who respond to the diagnostic – saves unnecessary expenses – saves unnecessary Prostate, patient stress Renal cancer Non-Hodgkin-Lymphoma Gastro • Strengthens nuclear physicians as a distribution channel Slides for Illustration – The spoken word shall be binding 18
But But: : Exp Expan ansion sion of of Indica Indication tion is Like is Likely ly to to Come Come Clinical studies with Lu-177 acc. to FDA, Phase II or higher, as of May 2019 19 https://clinicaltrials.gov/ct2/results?term=lutetium&age_v=&gndr=&type=&rslt=&phase=1&phase=2&Search=Apply Slides for Illustration – The spoken word shall be binding
Numb Number er of Diagn of Diagnos oses es Cou Could ld Sud Sudde denly nly Incr Increa ease se • Diagnosis is key to therapy details • Retreatment likely – Diagnosis and therapy control may add up to ø 2 scans/ patient? https://www.itnonline.com/content/theragnostics-reports-positive-clinical-trial-results-prostate-cancer-study 20
INTE INTERVE RVENTI NTIONAL ONAL RADIOLOG RADIOLOGY Dying decently Slides only for illustration – the spoken word shall be binding 21
Principle Principle of Invert of Inverted ed Tree Tree Pellets/spheres are proprietary Radioactive loading done by Eckert & Ziegler
Hug Huge Numb Number er of of Cas Cases es in China in China At Attr trac active tive Reimbu Reimburs rsemen ement China 280,000 men 100,000 women ~380,000 cases per year (!) Reimbursement China ~ 11,000 US$/ patient Age-standardized incidence rates of hepatocellular carcinoma per 100,000 populations at risk, in different regions of world (Source: GLOBOCAN 2002). Slides for Illustration – The spoken word shall be binding 23
Numerou Numerous Medica s Medical l Device Device Co Compa mpanies nies Start the Sta rt their ir own own P Prog rograms rams and much more …. Slides for Illustration – The spoken word shall be binding
Fitt Fitting ing Well Well into into the the Pictu Picture re Isotop • Bayer/ ALGETA 2,1 Mrd. USD Ra-223 – (2014) • IPSEN/ OPS 0,1 Mrd. USD Ge-68 – 2015 • NOVARTIS/ AAA Ge-68 4,0 Mrd. USD – (2017) • NOVARTIS/ Endocyte Lu-177 2,1 Mrd. USD – 2017 • GCP/ SIRTEX Y-90 1,4 Mrd. USD – June 2018 • Boston Scientific/ BTG 4,2 Mrd. USD Y-90 – November 2018 • Bracco/ Blue Earth F-18 0,5 Mrd. EUR – April 2019 Slides for Illustration – The spoken word shall be binding
M&A M&A Acti Activiti vities es Fu Full ll Spe Speed ed Ahea Ahead d in 2 in 201 019 9 as We as Well ll Isotop • Bayer/ ALGETA 2,1 Mrd. USD Ra-223 – (2014) • IPSEN/ OPS 0,1 Mrd. USD Ge-68 – 2015 • NOVARTIS/ AAA Ge-68 4,0 Mrd. USD – (2017) • NOVARTIS/ Endocyte Lu-177 2,1 Mrd. USD – 2017 • GCP/ SIRTEX Y-90 1,4 Mrd. USD – Juni 2018 • Boston Scientific/ BTG 4,2 Mrd. USD Y-90 – November 2018 • Bracco/ Blue Earth F-18 0,5 Mrd. EUR – April 2019 Slides for Illustration – The spoken word shall be binding
Thank Thank you you! Slides for Illustration – The spoken word shall be binding 27
Fina Financ ncial ial Calen Calenda dar / I / IR-Con Conta tact ct 31.03.2020 Publication FY2019 Eckert & Ziegler AG 12.05.2020 Quarterly Report I Karolin Riehle May 2020 Spring Conference in Frankfurt Investor Relations & PR 17.06.2020 Annual General Meeting in Berlin Robert-Rössle-Str. 10 13.08.2020 Quarterly Report II D-13125 Berlin 10.11.2020 Quarterly Report III Tel. +49 30 94 10 84-138 Fax +49 30 94 10 84-112 karolin.riehle@ezag.de www.ezag.com ISIN DE0005659700 Reuters EUZ.DE Slides for Illustration – The spoken word shall be binding 28
Recommend
More recommend
